ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · FRα
Relapsed Neuroblastoma; Refractory Neuroblastoma · FRα
Relapsed/Refractory Myeloma · BCMA
Relapsed/Refractory; Multiple Myeloma · BCMA
Relapsed or Refractory Hodgkin Lymphoma · FRα
Relapsed or Refractory Plasma Cell Neoplasms · BCMA
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Relapsed/Refractory B-cell ALL · FRα
Relapsed/Refractory Multiple Myeloma; Relapsed/Refractory Plasma Cell Leukemia · FRα
Multiple Myeloma; Relapsed/Refractory · FRα
Relapsed/Refractory B-cell Lymphoma · FRα
Relapsed Non Hodgkin Lymphoma · PD-1
Relapsed or Refractory Plasma Cell Neoplasms; Lymphomas/Leukemias With Plasmacytic Differentiation · BCMA
Relapsed or Refractory Multiple Myeloma · CD38
Relapsed or Refractory B Cell Leukemia and Lymphoma · FRα
Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα
Relapsed Adult Myeloid Leukemia; Chemotherapy Refractory Adult Myeloid Leukemia · FRα
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL); Refractory B Cell Acute Lymphoblastic Leukemia (ALL) · CD19
Relapsed and Refractory B-cell Lymphoma · CD19
Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin's Lymphoma, Relapsed · CD19
4 / 8 pages
구조모아 (StructureMoa)항암 chemical structure spider web
KRMediMoa한의학·한약재 임상·근거 데이터
다음 갱신 D-6 · 마지막 9월 2일 · 방문 855 / 70,689